Preeklampside Epoksieikozatrienoik asit Metabolizması
Amaç: Preeklampsi (PE) hamilelik sırasında hipertansiyon ve proteinüri ile karakterize bir hastalıktır. Epoksieikozatrienoik asitler (EET) vazodilatatör, antienflamatuar ve profibrinolitik etkiye sahip araşidonik asit metabolitleridir. Çözünür epoksit hidrolaz (çEH EC 3.3.3.2) EET’ lerin inaktif diollerine (DHET’ ler) yıkımını katalizler. EET’ lerin düşük dolaşım düzeyleri preekalampsideki yüksek kan basıncıyla ilişkili olabilir. Bu çalışmanın amacı preeklampsi hastalarında EET’ lerin çEH aracılı metabolizmasının temsili bir metaboliti olan 11,12-DHET düzeylerinini belirlenmesidir. Yöntem: 75 PE hastası ve control grubu olarak 75 normotansif gebe kadının plazma örnkelerinde 11,12-DHET düzeyleri ELISA yöntemi ile ölçüldü. Bulgular: PE hastalarının plazma 11,12-DHET düzeylerinin control grubuna kıyasla analmalı olarak yükseldiği saptandı. Sonuç: Bu sonuçlar ve daha önceki bulgularımız PE hastalarında yüksek çEH aktivitesinin daha fazla 11,12-DHET üretimine neden olduğuna işaret etmektedir. Yüksek katalitik aktiviteli çEH enzimi, EET’ lerin hızlı yıkımı yoluyla bu moleküllerin vazodilatatör, antihipertansif, antienflamatuar etkilerinin azalmasına katkı sağlayarak PE patogenizinde bir rol oynuyor olabilir.
Epoxyeicosatrienoic acid Metabolism in Preeclampsia
Objective: Preeclampsia (PE) is a disease that characterized by hypertension and proteinuria during pregnancy.Epoxyeicosatrienoic acids (EETs) are arachidonic acid metabolites which have vasodilatator, anti-inflammatory andprofibrinolytic effects. Soluble epoxide hydrolase (sEH; EC 3.3.3.2) catalyses the degradation of EETs to their inactivediols (DHETs). Low circulating levels of EETs may be related to high blood pressure in preeclampsia. The aim of thisstudy is to determine the level of 11,12-DHETs, a representative metabolite of sEH-mediated metabolism of EET, inpreeclamptic patients.Method: 11,12-DHET levels were measured by ELISA in plasma samples of 75 PE patients and 75 normotensivepregnant women as controls.Results: It was found that lasma 11,12-DHET levels of PE patients was significantly increased compared to the controlgroup (p
___
- Choudhury M, Friedman JE. Epigenetics
and microRNAs in preeclampsia. Clinical
and experimental hypertension 2012; 34:
334-41.
- Redman CW, Sargent IL. Latest advances
in understanding preeclampsia. Science
2005; 308: 1592–4.
- Sibai B, Dekker G, Kupferminc M. Preeclampsia.
Lancet. 2005; 365: 785–99.
- Zoet GA, Koster MP, Velthuis BK, de
Groot CJM, Maas AHEM, Fauser BCJM,
Franx A, van Rijna BB. Determinants of
future cardiovascular health in women
with a history of preeclampsia.
Maturitas 2015; 82: 153-61.
- Gongora MC, Wenger NK.
Cardiovascular complications of
pregnancy. International journal of
molecular sciences 2015; 16: 23905-28.
- Lee G, Tubby J. Preeclampsia and the risk
of cardiovascular disease later in life–A
review of the evidence. Midwifery 2015;
31: 1127-34.
- Wang A, Rana S, Karumanchi SA.
Preeclampsia: the role of angiogenic
factors in its pathogenesis.
Physiology 2009; 24: 147-58.
- Hermes W, Van Kesteren F, De Groot CJ.
Preeclampsia and cardiovascular
risk. Minerva ginecologica 2012; 64: 281-
92.
- VanWijk MJ, Kublickiene K, Boer K,
VanBavel E. Vascular function in
preeclampsia. Cardiovascular
research 2000; 47: 38-48.
- Gilbert JS, Ryan MJ, LaMarca BB,
Sedeek M, Murphy SR, Granger JP.
Pathophysiology of hypertension during
preeclampsia: linking placental ischemia
with endothelial dysfunction. American
Journal of Physiology-Heart and
Circulatory Physiology 2008: 294; H541-
H550.
- Furchgott RF, Zawadzki JV. The
obligatory role of endothelial cells in the
relaxation of arterial smooth muscle by
acetylcholine. Nature 1980; 5789: 373-76.
- Moncada S, Vane JR. The role of
prostacyclin in vascular tissue. Federation
proceedings 1979; 38: 66-71.
- Feletou M, Vanhoutte PM.
Endothelium-dependent hyperpolarization
of canine coronary smooth muscle. British
journal of pharmacology 1988; 93: 515-
24.
- Fiona Lyall and Ian A. Greer The vascular
endothelium in normal pregnancy and
pre-eclampsia. Reviews of Reproduction
1996; 1: 107–116.
- Sibai B, Dekker G, Kupferminc M.
Preeclampsia. Lancet 2005; 365: 785–
799.
- Yang L, Mäki-Petäjä K, Cheriyan J,
McEniery C, Wilkinson IB. The role of
epoxyeicosatrienoic acids in the
cardiovascular system. British journal of
clinical pharmacology 2015; 80: 28-44
- Fisslthaler B, Popp R, Kiss L, Potente M,
Harder DR, Fleming I, Busse R.
Cytochrome P450 2C is an EDHF
synthase in coronary arteries.
Nature 1999; 6752: 493-7.
- Popp R, Fleming I, Busse R. Pulsatile
stretch in coronary arteries elicits release
of endotheliumderived hyperpolarizing
factor: A modulator of arterial
compliance. Circ Res 1998; 82:696–703.
- Archer SL, Gragasin FS, Wu X, Wang S,
McMurtry S, Kim DH, Platonov M,
Koshal A, Hasimoto K, Campbell WB,
Falck JR, Michelakis ED. Endotheliumderived
hyperpolarizing factor in human
internal mammary artery is 11,12-
epoxyeicosatrienoic acid and causes
relaxation by activating smooth muscle
BKca channels. Circulation 2003;
107:769–776.
- Coats P, Johnston F, MacDonald J,
McMurray JJV, Hillier C. Endotheliumderived
hyperpolarizing factor: Identification and
mechanism of action in human
subcutaenous resistance arteries.
Circulation 2001; 103: 1702–1708.
- Miura H, Wachtel RE, Liu Y, Loberiza J,
F. R, Saito T, Miura M, Gutterman DD.
Flow-induced dilation of human coronary
arterioles: Important role of Ca2+-
activated K+ channels. Circulation 2001;
103:1992–1998.
- Campbell WB, Gebremedhin D, Pratt PF,
Harder DR. Identification of
epoxyeicosatrienoic acids as endotheliumderived
hyperpolarizing factors. Circ Res
1996; 78: 415–423.
- Huang A, Sun D, Jacobson A, Carroll
MA, Falck JR, Kaley G.
Epoxyeicosatrienoic acids are released to mediate shear stress-dependent
hyperpolarization of arteriolar smooth
muscle. Circ Res 2005; 96: 376–383.
- Gauthier KM, Edwards EM, Falck JR,
Reddy DS, Campbell WB. 14,15-
Epoxyeicosatrienoic acid represents a
transferable endothelium-dependent
relaxing factor in bovine coronary
arteries. Hypertension. 2005; 45: 666–
671.
- Imig JD. Epoxides and soluble epoxide
hydrolase in cardiovascular physiology.
Physiological reviews. 2012;92: 101-30.
- Wang D, DuBois RN.
Epoxyeicosatrienoic acids: a doubleedged
sword in cardiovascular diseases
and cancer. The Journal of clinical
investigation 2012; 122: 19-22.
- Oni-Orisan A, Alsaleh N, Lee CR,
Seubert JM. Epoxyeicosatrienoic acids
and cardioprotection: the road to
translation, Journal of molecular and
cellular cardiology 2014; 74: 199-208.
- Schaefer WR, Werner K, Schweer H,
Schneider J, Arbogast E, Zahradnik HP.
Cytochrome P450 metabolites of
arachidonic acid in human placenta.
Prostaglandins 1997; 54: 677–87.
- Patel L, Sullivan MH, Elder MG.
Production of epoxygenase metabolite by
human reproductive tissues.
Prostaglandins 1989; 38: 615–24.
- Gerber RT, Anwar MA, Poston L.
Enhanced acetylcholine induced
relaxation in small mesenteric arteries
from pregnant rats: an important role for
endothelium-derived hyperpolarizing
factor (EDHF). Br J Pharmacol 1998;
125: 455–60.
- Houli Jiang, John C. McGiff, Cristiano
Fava, Gabriella Amen, Elisa Nesta,
Giovanni Zanconato, John Quilley, Pietro
Minuz. Maternal and Fetal
Epoxyeicosatrienoic Acids in
Normotensive and Preeclamptic
Pregnancies American Journal of
Hypertension 2013; 26: 271-278.
- Catella F, Lawson JA, Fitzgerald DJ,
Fitzgerald GA. Endogenous biosynthesis
of arachidonic acid epoxides in humans:
Increased formation in pregnancy-induced
hypertension. Proc. Nati. Acad. Sci 1990;
87: 5893-5897.
- Zhou Y, Chang HH, Du J, Wang CY,
Dong Z, Wang MH. Renal
epoxyeicosatrienoic acid synthesis during
pregnancy. American Journal of Physiology-Renal Physiology 2005; 288:
221-226.
- Spector AA, Fang X, Snyder GD,
Weintraub NL. Epoxyeicosatrienoic acids
(EETs): metabolism and biochemical
function. Progress in Lipid
Research 2004; 43: 55-90.
- Sari I, Pinarbasi H, Pinarbasi E, Yildiz C.
Association between the soluble epoxide
hydrolase gene and preeclampsia.
Hypertens Pregnancy 2017;
doi.org/10.1080/10641955.2017.1388390.
- American College of Obstetricians and
Gynecologists. Hypertension in
pregnancy. Report of the American
college of obstetricians and
gynecologists’ task force on hypertension
in pregnancy. Obstetrics and
gynecology 2013; 122: 1122.
- Roman RJ. P-450 metabolites of
arachidonic acid in the control of
cardiovascular function. Physiol Rev
2002; 82: 131–85.
- Zeldin DC. Epoxygenase Pathways of
Arachidonic Acid Metabolism
J Biol Chem 2001; 276: 36059–62.
- Przybyla-Zawislak BD, Srivastava
PK, Vázquez-Matías J, Mohrenweiser
HW, Maxwell JE, Hammock
BD, BradburyJA, Enayetallah AE, Zeldin
DC, Grant DF. Polymorphisms in Human
Soluble Epoxide Hydrolase. Molecular
Pharmacology 2003; 64: 482–90.
- Fava C, Montagnana M, Danese E, Almgr
en P, Hedblad B, Engström G, Göran B,
Minuz, Pietro M, Olle M. Homozygosity
for the EPHX2 K55R polymorphism
increases the long-term risk of ischemic
stroke in men: a study in Swedes.
Pharmacogenetics and genomics 2010;
20: 94-103.
- Lee CR1, North KE, Bray MS, Fornage
M, Seubert JM, Newman JW, Hammock
BD, Couper DJ, Heiss G, Zeldin DC.
Genetic variation in soluble epoxide
hydrolase (EPHX2) and risk of coronary
heart disease: The Atherosclerosis Risk in
Communities (ARIC) study. Hum. Mol.
Genet 2006; 15: 1640-9.
- Pietro Minuz, Houli Jiang, Cristiano
Fava, Lucia Turolo, Stefania
Tacconelli, Marco Ricci, Paola
Patrignani, Alberto Morganti, Alessandro
Lechi, McGiff JC. Altered Release of
Cytochrome P450 Metabolites of
Arachidonic Acid in Renovascular Disease Hypertension 2008; 51: 1379–
1385
- Staff AC, Dechend R, Pijnenborg R.
Learning From the Placenta Acute
Atherosis and Vascular Remodeling in
Preeclampsia–Novel Aspects for
Atherosclerosis and Future
Cardiovascular Health.
Hypertension 2010; 56: 1026-34.